EUVIMEDEUVIMED entdecken
Crossref

Aramchol enhances proteosome inhibitor lethality in myeloma cells in vitro.

Paul Dent, Michael R Booth, Laurence Booth, Jane L Roberts

Medical Research Archives · 2026

DOI: 10.18103/mra.2026.0813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Paul Dent und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aramchol inhibits Stearoyl-CoA desaturase (SCD1) and has anti-cancer properties in GI tumor cells. In multiple myeloma cells aramchol interacted with the proteosome inhibitors bortezomib and carfilzomib in a greater-than-additive fashion to kill. Aramchol caused significantly greater activations of ATM and the AMPK in myeloma cells compared to prior findings obtained in GI tumor cell types. The aramchol-induced activations of ATM and the AMPK were not further enhanced by bortezomib. As a single agent aramchol caused an equivalent to a significantly greater inactivation of mTORC1 and mTORC2 compared to GI tumor cells, but exhibited only a modest further inactivation when combined with bortezomib. Knock down of ATM or AMPK alpha reduced killing caused by aramchol, bortezomib or when the drugs were combined. Unlike GI tumor cells, knock down of neither Beclin1 nor ATG5 suppressed aramchol lethality, though these interventions did significantly reduce killing caused by bortezomib and its combination with aramchol. Aramchol lethality was reduced by knock down of BAX or BAK but not by BIM whereas knock down of BAX, BAK, BIM and BID, as well as the death receptor CD95 reduced bortezomib lethality, with loss of BID or CD95 abolishing the drug interaction. Thus, aramchol lethality as a single agent in myeloma cells requires signaling by ATM and the AMPK, but not per se by enhanced macroautophagy. The lethal interaction between aramchol and bortezomib obligatorily requires CD95-BID signaling to the mitochondrion, where cleaved BID will cooperate with BAX and BAK to cause pore formation followed by myeloma cell execution

Zitieren

APA

Dent, P., Booth, M. R., Booth, L., & Roberts, J. L. (2026). Aramchol enhances proteosome inhibitor lethality in myeloma cells in vitro. Medical Research Archives. https://doi.org/10.18103/mra.2026.0813

Vancouver

Dent P, Booth MR, Booth L, Roberts JL. Aramchol enhances proteosome inhibitor lethality in myeloma cells in vitro. Medical Research Archives. 2026. doi:10.18103/mra.2026.0813

BibTeX
@article{Dent2026,
  author = {Dent, Paul and Booth, Michael R and Booth, Laurence and Roberts, Jane L},
  title = {Aramchol enhances proteosome inhibitor lethality in myeloma cells in vitro},
  journal = {Medical Research Archives},
  year = {2026},
  doi = {10.18103/mra.2026.0813}
}
Kostenlos starten →